Systimmune

We are a clinical-stage biopharmaceutical company at the forefront of cancer treatment innovation. Founded in 2014 and headquartered in Redmond, Washington, with a presence in Princeton, New Jersey, our focus is on the development of groundbreaking bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our mission is to create powerful biologics that not only directly target and attack tumors but also activate the patient's own immune system to bolster the anti-tumor response. We are a dedicated and multidisciplinary team, bringing together R&D scientists, clinical experts, and seasoned biotech business professionals who are all committed to developing world-class, antibody-based therapies. By harnessing advanced technology platforms and maintaining a strong operational presence in both the United States and China, we are able to facilitate rapid and cost-effective clinical development, with the ultimate goal of delivering transformative treatments to patients across the globe.

Our pipeline is robust and ambitious, with several assets currently in various stages of clinical trials for both solid tumors and hematologic indications. A cornerstone of our research is the development of potentially first-in-class treatments, such as our EGFRxHER3 bispecific ADC, BL-B01D1. This innovative approach targets multiple proteins highly expressed in epithelial tumors, aiming to overcome treatment resistance and improve patient outcomes. We are proud of our strategic collaborations, including a significant partnership with Bristol Myers Squibb to co-develop and co-commercialize BL-B01D1, a testament to the potential of our science. This collaboration enhances our ability to advance our therapeutic candidates and expands our reach to a global patient population. As we continue to scale our organization and strengthen our capabilities, we remain steadfast in our commitment to pioneering the next generation of breakthrough cancer therapies and making a meaningful difference in the lives of those affected by this devastating disease.